All In Biotech

Drug Trial Radar · NCT00131404

A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)

A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant in Obese Patients Followed by a 1-Year Extension

Last checked: Nov 19, 2026Latest source record: Feb 5, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 2,400 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,400

Actual

Start

Sep 2005

Primary completion

Feb 2007

Study completion Dec 2008

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 18, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to determine the safety and efficacy of an investigational drug in patients with obesity plus extension.

Conditions

  • Obesity

Interventions

  • taranabantDrug

    taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.

  • Comparator: PlaceboDrug

    Placebo capsule once daily. 52 week treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Decreases body weight; safety and tolerabilityTime frame: 156 Weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.